WO2021238836A1 - Préparation antivirale et antibactérienne de cantharidine, son procédé de préparation, et son utilisation pour prévenir et traiter une nouvelle infection à coronavirus - Google Patents

Préparation antivirale et antibactérienne de cantharidine, son procédé de préparation, et son utilisation pour prévenir et traiter une nouvelle infection à coronavirus Download PDF

Info

Publication number
WO2021238836A1
WO2021238836A1 PCT/CN2021/095429 CN2021095429W WO2021238836A1 WO 2021238836 A1 WO2021238836 A1 WO 2021238836A1 CN 2021095429 W CN2021095429 W CN 2021095429W WO 2021238836 A1 WO2021238836 A1 WO 2021238836A1
Authority
WO
WIPO (PCT)
Prior art keywords
cantharidin
oil
solution
mutual
water
Prior art date
Application number
PCT/CN2021/095429
Other languages
English (en)
Chinese (zh)
Inventor
王卫
Original Assignee
甘肃芫美药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010446540.8A external-priority patent/CN111568897A/zh
Application filed by 甘肃芫美药业有限公司 filed Critical 甘肃芫美药业有限公司
Publication of WO2021238836A1 publication Critical patent/WO2021238836A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • the invention relates to the field of biopharmaceuticals, in particular to provide a cantharidin antiviral and antibacterial preparation and a preparation method thereof.
  • the preparation provided by the invention can be used as antiviral and antibacterial preventive and therapeutic drugs. In particular, it will also have an important preventive and therapeutic effect on the infection of pathogens such as the new coronavirus, influenza virus, Ebola virus, and HIV.
  • Cantharidin is an animal's defensive substance. It is a high-efficiency, low-toxicity, broad-spectrum antiviral and antibacterial bioactive raw material drug, which has been recorded in Chinese medicine for a long time.
  • Cantharidin is also a kind of raw material of modern western medicine. A hundred years ago, Western medical scientists have purified cantharidin and studied its physical properties and chemical structure. Clinically, this defensive substance of the genus Lycane insects was classified as a "skin irritant, blistering drug".
  • cantharidin cream has significant antipyretic, antiemetic and antidiarrheal effects in the treatment of children's autumn diarrhea.
  • the effective rate was 97% within 48 hours, the average improvement time was 23.4 hours, the antiemetic time was 19.7 hours, and the antipyretic time was 18.75 hours, which significantly shortened the course of the disease.
  • External treatment can also avoid the difficulty of taking medicine caused by vomiting in children. During the treatment, no local adverse skin reactions and other side effects were found.
  • “Cantharidin Cream” is a safe and effective medicine for treating infantile diarrhea.
  • cantharidin antiviral and antibacterial series preparations In the development of cantharidin antiviral and antibacterial series preparations and the search for solvent carriers of cantharidin, the inventors studied the application of fats and essential oils to prepare cantharidin antiviral and antibacterial series preparations, and obtained ZL90106365.7 and 01140066.8 patents. However, the development of cantharidin antiviral and antibacterial series preparations, the search for the solvent carrier of cantharidin, until the application of essential oils, is far from obtaining an ideal cantharidin solvent carrier.
  • the maximum solubility of cantharidin in water is 33.33ppm; after more than 50 years of research in this medical research project, pure water is used as the solvent carrier of cantharidin to prepare a formulation of cantharidin human in vitro target efficacy. When its water evaporates, its highest The drug concentration can reach 33.33ppm. Compared with the long-term large number of cantharidin toxicology studies in this subject, compared with the data of the target drug concentration of cantharidin in the human body ⁇ 5.6ppm, it is obvious that the drug concentration is too high. Therefore, cantharidin preparations that are simply dissolved in water become "blistering agents" with toxic and side effects when applied to targets outside the body, and cannot produce the therapeutic effects that cantharidin should have.
  • the present invention selects oil-oil mutual soluble and oil-water mutual solubles as the solvent carrier of cantharidin, and obtains significant advantages in cantharidin pharmacy, toxicology, and pharmacodynamics than the oils and essential oils used in the ZL90106365.7 and 01140066.8 invention patents. improve.
  • the first aspect of the present invention is to provide an antiviral and antibacterial cantharidin preparation containing cantharidin as an effective drug Ingredients, the cantharidin is dissolved in an oil-water mutual soluble or an oil-oil mutual soluble to obtain a cantharidin solvent carrier, and the cantharidin solvent carrier is formulated with a pharmaceutically acceptable carrier or excipient into a variety of dosage forms for the prevention and treatment of new crowns Viral drugs.
  • the oil-water mutual solution or the oil-oil mutual solution contains essential oils of ketones and/or lactones.
  • the second aspect of the present invention is to provide a cantharidin skin absorption lotion for the prevention and treatment of new coronavirus, which contains cantharidin as an effective pharmaceutical ingredient, and the solvent carrier of cantharidin is an oil-water mutual solution, including:
  • Ketone essential oil 40.0-60.0g
  • a transdermal absorption lotion containing 0.16-0.2mg of cantharidin per gram is prepared.
  • the third aspect of the present invention is to provide an intravenous injection for the treatment of neocoronavirus with an oil-water mutual solution as a solvent carrier of cantharidin, which contains cantharidin as an effective pharmaceutical ingredient, according to the following ingredients:
  • the rest is physiological water for injection: total 16000.00g.
  • the fourth aspect of the present invention is to provide a cantharidin tablet with a cantharidin solvent carrier as a cantharidin solvent for the treatment of new coronaviruses, containing cantharidin as an effective drug ingredient, including:
  • Cocoa butter 80.0-120.0g
  • the fifth aspect of the present invention is to provide a cantharidin capsule for the treatment of the new coronavirus, with an oil-oil mutual soluble as a cantharidin solvent carrier, which contains cantharidin as an effective pharmaceutical ingredient, including:
  • the sixth aspect of the present invention is to provide a cantharidin nasal and eye spray which is used as the prevention of new coronavirus, and the oil-water mutual soluble solvent is the solvent carrier of cantharidin, which contains cantharidin as an effective drug ingredient, which includes:
  • the balance is distilled water: a total of 10000.0g cantharidin nose and eye spray.
  • the seventh aspect of the present invention is to provide a cantharidin nasal and ophthalmic oil for the prevention of new coronaviruses, the oil-oil mutual soluble as the solvent carrier of cantharidin, which contains cantharidin as an effective pharmaceutical ingredient, and includes:
  • the rest is olive oil: a total of 1000.0g cantharidin nose and eye oil is made.
  • the eighth aspect of the present invention is to provide a cantharidin solution disinfectant cloth used as a prevention of new coronavirus, oil-water mutual soluble as cantharidin solvent carrier, containing cantharidin as an effective drug ingredient, including:
  • the remainder is distilled water, making 10000.0g.
  • the obtained solvent is sprayed on the carrier to prepare a cantharidin solution disinfection cloth towel.
  • the ninth aspect of the present invention is to provide a combined oral pill of cantharidin Chinese and Western medicine for the treatment of new coronavirus, which contains cantharidin as an effective drug ingredient, and the solvent carrier of cantharidin is an oil-oil mutual soluble substance, according to the following ingredients:
  • Cocoa butter 10.0g
  • Cantharidin lysate (containing cantharidin 330.0mg): 126.0g
  • Astragalus extract 100.0g
  • the tenth aspect of the present invention is to provide a cleaning agent prepared by families and soldiers who are mutually soluble in oil and water to prevent traumatic infections, characterized in that the solution is a cantharidin oil-water mutual soluble body, and has the following components:
  • the eleventh aspect of the present invention is to provide a cantharidin antiviral and antibacterial invisible condom for preventing HIV sexual transmission. It is characterized in that the solution is a cantharidin oil-water mutual solution, and has the following ingredients:
  • Lactic acid 1000.0g
  • Hyaluronic acid 30.0-120.0g
  • the remainder is distilled water to make: a total of 10000.0g cantharidin invisible condom for preventing HIV sexual transmission.
  • the twelfth aspect of the present invention is to provide a cantharidin antibiotic solution for preparing an anti-new coronavirus inactivated vaccine, which contains cantharidin as an effective drug ingredient, and is a solution containing 1.6 ppm ⁇ cantharidin ⁇ 3.6 ppm.
  • the solution containing 1.6 ppm ⁇ cantharidin ⁇ 3.6ppm is a cantharidin oil-oil mutual soluble or a cantharidin oil-water mutual soluble.
  • the oil-oil mutual solution is a cantharidin solvent carrier, including: 2-butanone and olive oil, the cantharidin content is 1.6-3.6 ppm, the 2-butanone content is 8-12% by weight, and the rest is The olive oil.
  • the oil-water mutual solution is a cantharidin solvent carrier, including: cantharidin, the content is 1.6-3.6ppm; ethanol, the content is 3.75-5.2% by weight; 2-butanone, the content is: 0.8-1.2% by weight; propylene glycol , The content is: 4.95-7.2 5 wt%; benzyl alcohol, the content is: 0.06-0.12 wt%; 2-phenylethanol, the content is: 0.06-0.12 wt%; the raspberry ketone, the content is: 0.03.-0.06% by weight ; The rest is distilled water.
  • cantharidin solvent carrier including: cantharidin, the content is 1.6-3.6ppm; ethanol, the content is 3.75-5.2% by weight; 2-butanone, the content is: 0.8-1.2% by weight; propylene glycol , The content is: 4.95-7.2 5 wt%; benzyl alcohol, the content is: 0.06-0.12 wt%; 2-phenylethanol,
  • the thirteenth aspect of the present invention is to provide a method for preparing a cantharidin antibiotic solution for preparing an anti-new coronavirus inactivated vaccine, which is to dissolve a certain amount of cantharidin and 2-butanone in olive oil, and then add the olive oil Until the cantharidin content is 1.6-3.6 ppm, the 2-butanone content is 8-12% by weight, and the rest is the cantharidin antibiotic solution of the olive oil.
  • the fourteenth aspect of the present invention is to provide a preparation method for preparing cantharidin antibiotic solution for inactivated vaccine against new coronavirus, which is to combine a certain amount of cantharidin with a content of 1.6-3.6 ppm; ethanol with a content of: 3.75-5.25 Weight%; 2-butanone, content: 0.8-1.2% by weight; Propylene glycol, content: 4.95-7.25% by weight; Benzyl alcohol, content: 0.06-0.12% by weight; 2-Phenylethanol, content: 0.06- 0.12% by weight; raspberry ketone, the content is: 0.03.-0.06% by weight; after being dissolved in distilled water, distilled water is added to obtain a cantharidin antibiotic solution.
  • the cantharidin solvent ⁇ 5.6 ppm of the present invention is used as a solution and can be used to manufacture antibiotic "ecological" inactivated vaccines.
  • the use of this solution does not use physical methods or chemical methods, but uses the ecological biological activity of the cantharidin solution to inactivate pathogens to make virus or bacterial inactivated vaccines.
  • the antigenicity of the present invention will be more ideal, and it is a new technical route for manufacturing inactivated vaccines that is highly worth testing.
  • Cantharidin is a refined cantharidin obtained according to the prior art (ZL patent number 90106365.7 or 01140066.8).
  • Ketone essential oil 40.0-60.0g
  • a skin absorption lotion containing 0.16-0.2mg of cantharidin per gram is prepared.
  • the skin absorption lotion contains 0.32-0.4 mg cantharidin.
  • the preparation enters the blood circulation through the lymphatic system, exerts a medicinal effect on the internal organs of cantharidin, and treats respiratory infections such as influenza with remarkable curative effect. It can be preferentially used to treat infections of viruses and bacteria such as new coronaviruses and influenza viruses.
  • the rest is physiological water for injection, made into a total of 16000.00ml.
  • cantharidin anti-infective preparations of the present invention For patients with lung virus and germ infection, it is suitable for alternate application or combination with other cantharidin anti-infective preparations of the present invention during rescue.
  • Daily intravenous injection of 100.0-160.0ml (based on the amount of cantharidin is 0.1-0.3mg per day). It can be used to treat infections of viruses and bacteria such as new coronaviruses and influenza viruses.
  • 60kg adults treat respiratory virus and bacterial infections, 2-3 times a day, 8-16 tablets each time, equivalent to 0.32-1.44mg pure cantharidin. It can be used to treat infections of viruses and bacteria such as new coronaviruses and influenza viruses.
  • the total amount produced 10,000 grains, each grain weighs 0.392-0.588g.
  • 60kg adults treat respiratory virus and bacterial infections, 2-3 times a day, 8-16 capsules each time, which is equivalent to 0.32-1.44mg pure cantharidin. It can be used to treat infections of viruses and bacteria such as new coronaviruses and influenza viruses.
  • distilled water made: a total of 10000.0g of cantharidin is a common trauma cleaning agent for families and soldiers to prevent infection.
  • the preparation can be used to clean wounds and prevent trauma infections, and has been proved to be very effective through long-term clinical practice. It can also be sprayed on the nose and eyes to prevent and treat infections of viruses and bacteria such as new coronaviruses and influenza viruses. It is the sanitary cleaning supplies for households and soldiers.
  • the remaining olive oil is made into: a total of 1000.0g cantharidin nose and eye oil.
  • the preparation can be used to bandage trauma. It has been used in hospital surgical treatment rooms and rural primary medical institutions for a long time. It has been used in medical institutions for a long time. In tens of thousands of clinical practice, there is no case of wound infection treated with this preparation, indicating that the preparation is used for trauma. , Can completely kill viruses and bacteria that can infect humans. It can be preferentially used to prevent infections of viruses and germs such as new coronaviruses and influenza viruses.
  • cantharidin solution disinfection cloth towel cantharidin is 1.0-2.6ppm
  • preparation method of oil-water miscible solution is as follows:
  • the remainder is distilled water to make a solution with a total amount of 10000.0g and a cantharidin content of 1.0-2.6ppm.
  • the cotton fabric is soaked with the above solution to obtain a cantharidin solution disinfection cloth towel.
  • the cloth towel can be used as the lining of personnel masks, etc., and is a disposable disinfection and protection product for protecting against new coronary pneumonia and other viruses. It can be preferentially used to prevent infections of viruses and germs such as new coronaviruses and influenza viruses.
  • Cocoa butter 10.0g
  • cantharidin oil-oil mixed solution which is used as the traditional Chinese and Western medicine Combines the main effective ingredients of pills.
  • Cantharidin lysate (containing cantharidin 330.0mg): 126.0g
  • Astragalus extract 100.0g
  • cantharidin oral pills combined with Chinese and Western medicine were prepared. Each pill contains 0.33mg cantharidin. 60kg adults 2-3 times a day, 1 pill each time, equivalent to a daily dose of 0.66-1.0mg cantharidin. It can be preferentially used to prevent infections of viruses and germs such as new coronaviruses and influenza viruses.
  • the pathogens can be put into the solution separately and in groups according to conventional techniques, protected from light, at a constant temperature of 34-36°C, and continue to carry out various methods of cantharidin antibiotics. Research and experiment on ecological inactivated vaccines.
  • Example 1 For 2 suspected persons with obvious symptoms of the new coronavirus, use the cantharidin skin absorption lotion prepared in Example 1 to apply 2.0g on the chest, back, and limbs of a 60kg adult three times a day, after applying it for 12 hours. , The body temperature dropped to 37.6 °C, after 24 hours, the body temperature dropped to normal. On the 2nd day of medication, symptoms of chest tightness and anorexia began to be significantly reduced. After 4 days of continuous medication, the suspected person's symptoms disappeared and returned to normal.
  • Example 2 To 8 suspected persons with mild chest tightness and dry cough symptoms, use the cantharidin skin absorption lotion prepared in Example 1 to apply 2.0g on the skin of the chest, back and limbs three times a day for a 60kg adult. After 1 day, the symptoms of fatigue and dry cough alleviated. After 3 days of application, the suspected person’s symptoms disappeared completely and returned to normal.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Insects & Arthropods (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une préparation antivirale et antibactérienne de cantharidine, contenant de la cantharidine en tant qu'ingrédient médicamenteux efficace. La cantharidine est dissoute dans une substance miscible huile-eau ou une substance miscible huile-huile pour obtenir un support de solvant cantharidine, et le support de solvant cantharidine est formulé avec un support ou un excipient pharmaceutiquement acceptable en différentes formes posologiques de médicaments antiviraux et antibactériens. Les médicaments peuvent être utilisés pour prévenir et traiter une nouvelle infection à coronavirus, et le support de solvant cantharidine peut également être utilisé en tant que solution pour préparer un vaccin écologique antibiotique inactivé contre un nouveau coronavirus.
PCT/CN2021/095429 2020-05-25 2021-05-24 Préparation antivirale et antibactérienne de cantharidine, son procédé de préparation, et son utilisation pour prévenir et traiter une nouvelle infection à coronavirus WO2021238836A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010446540.8 2020-05-25
CN202010446540.8A CN111568897A (zh) 2020-05-25 2020-05-25 一种斑蝥素抗病毒、抗菌制剂、其制备方法及用作预防和治疗新冠病毒感染
CN202110545158.7 2021-05-19
CN202110545158.7A CN113855668A (zh) 2020-05-25 2021-05-19 一种斑蝥素抗病毒、抗菌制剂、其制备方法及用作预防和治疗新型冠状病毒感染

Publications (1)

Publication Number Publication Date
WO2021238836A1 true WO2021238836A1 (fr) 2021-12-02

Family

ID=78722974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/095429 WO2021238836A1 (fr) 2020-05-25 2021-05-24 Préparation antivirale et antibactérienne de cantharidine, son procédé de préparation, et son utilisation pour prévenir et traiter une nouvelle infection à coronavirus

Country Status (1)

Country Link
WO (1) WO2021238836A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1421202A (zh) * 2001-11-23 2003-06-04 王卫 一种抗病毒、抗菌的斑蝥酸酐药物组合物及其制备方法
CN1449752A (zh) * 2003-05-09 2003-10-22 王卫 用于治疗和预防非典型肺炎传染病的斑蝥总酸酐制剂及其制备
CN111568897A (zh) * 2020-05-25 2020-08-25 甘肃芫美药业有限公司 一种斑蝥素抗病毒、抗菌制剂、其制备方法及用作预防和治疗新冠病毒感染

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1421202A (zh) * 2001-11-23 2003-06-04 王卫 一种抗病毒、抗菌的斑蝥酸酐药物组合物及其制备方法
CN1449752A (zh) * 2003-05-09 2003-10-22 王卫 用于治疗和预防非典型肺炎传染病的斑蝥总酸酐制剂及其制备
CN111568897A (zh) * 2020-05-25 2020-08-25 甘肃芫美药业有限公司 一种斑蝥素抗病毒、抗菌制剂、其制备方法及用作预防和治疗新冠病毒感染

Similar Documents

Publication Publication Date Title
CN113855668A (zh) 一种斑蝥素抗病毒、抗菌制剂、其制备方法及用作预防和治疗新型冠状病毒感染
KR20190122562A (ko) 바이러스성 질환의 치료 또는 경감을 위한 약학적 조성물과 식품 조성물
US20170258861A1 (en) Treatment of Herpes, Pseudomonas, Staph, and Hepatitis
US20070248619A1 (en) New pharmaceutical composition from natural materials for regulating immunity, its preparation method and use
WO2009099405A2 (fr) Compositions antibactériennes et procédés de traitement
CN105168361A (zh) 一种治疗烧烫伤的植物油复方擦剂及其制备方法
CN106377602A (zh) 一种铁皮石斛复合消毒粉及制备方法和使用方法
WO2021238836A1 (fr) Préparation antivirale et antibactérienne de cantharidine, son procédé de préparation, et son utilisation pour prévenir et traiter une nouvelle infection à coronavirus
CN106237029B (zh) 一种芦荟抗菌凝胶及其制备方法
US20210401773A1 (en) ye-COVIDICIN Botanical and Traditional Medicine to Treatment for COVID-19
CN112402500A (zh) 一种中药制剂在预防和消杀冠状病毒中的应用
CN106265713A (zh) 虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物
CUTTING et al. The alleged efficiency of medicinal treatment of typhoid carriers
US20230102810A1 (en) The use of unripened green mangifera indica as a natural preparation to treat sars-cov-2
US20220047663A1 (en) Formulation for inhibiting virus replication
CN106955280A (zh) 一种防治副猪嗜血杆菌病的药物及其应用
CN115919825A (zh) 一种油溶性蚁酸作抗病毒、抗菌原料的药剂、及其制备方法
CN107648249B (zh) 去半乳糖替告皂甙在制备防治流感病毒感染的药物中的应用
JP2002265354A (ja) 抗ピロリ菌剤組成物
AU2008241370B2 (en) Essential oil of kunzea ambigua and methods of use
WO2016119089A1 (fr) Médicament pour le traitement du syndrome d'immunodéficience acquise et procédé de préparation
CN107648226A (zh) 一种治疗偏头痛的药物组合物及其制备方法
CN114767664A (zh) 一种用于治疗新型冠状病毒的干粉状药物
CN111450197A (zh) 一种含乙醇的纯中药外用消毒液配方
CN115337308A (zh) Acss2抑制剂在制备抗h1n1亚型猪流感病毒药物中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21812789

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21812789

Country of ref document: EP

Kind code of ref document: A1